Antimicrobial Agents and Chemotherapy · 2015 · 107 citations · 20 references
Life SciencesInfectious DiseasesPharmacologyAntimicrobial ResistanceInfectious Disease EpidemiologyMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceAntimicrobial Susceptibility TestingBacterial EpidemiologyCarbapenem ResistanceResistance SurveillanceAmpc Beta-lactamasesAntibiotic Susceptibility TestingAntimicrobial Resistance MonitoringEscherichia ColiEscherichia Coli ResistanceExtended-spectrum Beta-lactamasesMultidrug-resistant OrganismsMultidrug-resistant Pathogens
Antimicrobial resistance in Enterobacteriaceae, including resistance to carbapenems, is increasing worldwide. However, using U.S. Study for Monitoring Antimicrobial Resistance Trends (SMART) data for 2009 to 2013, no statistically significant decreasing susceptibility trends were found overall for Escherichia coli isolates from patients with intra-abdominal infections. In the subset of isolates from community-associated infections, susceptibility to levofloxacin decreased significantly and the increasing rate of multidrug-resistant E. coli approached statistical significance. In 2013, ertapenem, imipenem, and amikacin showed the highest susceptibility rates (≥99%) and fluoroquinolones the lowest (<70%). The 10 non-ertapenem-susceptible isolates (0.3% of all E. coli isolates) encoded one or more carbapenemases, extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, or non-ESBL β-lactamases.
20
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey et al. · Clinical Microbiology and Infection · 2011 · 14K citations
Joseph S. Solomkin, John E. Mazuski, John S. Bradley et al. · Surgical Infections · 2010 · 631 citations